Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Remote sampling

Home blood test for Alzheimer's shows promise

An international study shows that Alzheimer’s disease biomarkers can be accurately detected using simple finger-prick blood samples that can be collected at home and mailed to a laboratory.

Article • Hospital hygiene

Breaking chains of infection to combat antimicrobial resistance

With antimicrobial resistance causing over 5 million deaths annually, rapid outbreak detection is critical. A German lab demonstrates how FTIR spectroscopy can transform hospital infection control.

News • Rapid diagnostics

New system simultaneously detects antibiotic resistence and virulence of K. pneumoniae

Now, a research team has developed a novel diagnostic approach that enables the rapid and simultaneous detection of both antibiotic resistance and high virulence in Klebsiella pneumoniae.